Latest News

Karolina Lempert, PhD

By Danny Yarnall

Karolina Lempert would like to know whom you trust.

She calls it “studying the neuroeconomics of long-term and short-term decision making in adults with cognitive decline.” Essentially, she is looking at how memory impacts judgment, part of new research she presented to Penn Memory Center (PMC) colleagues.

Lempert, PhD, talks a lot about economics. For her, the subject is intertwined with the realities of daily living whether we like it or not, but with one tweak in language to describe neuroeconomics — a combination of psychology, neuroscience, and economics.

“I like to use models and ideas from economics and see how people actually behave, which is a little different from classical economics, which is about how people should behave,” Dr. Lempert said. “We make decisions with our brain, so understanding how it works helps us understand more about our behavior.”

The Penn Memory Center hosted a Book Club meeting January 9 to discuss The Soul of Care: The Moral Education of a Husband and a Doctor, written by Harvard anthropologist and writer Arthur Kleinman, MD.

PMC Co-Director Jason Karlawish, MD, and PMC Scholar Emily Largent, RN, JD, PhD were joined by PMC and Penn Medicine faculty and staff, as well as caregivers of PMC patients. Discussion centered around the personal narrative of Kleinman’s caregiving experience in the book and drawing on the writings to apply to their own lives and careers in medicine.

The book club was a companion to Arthur Kleinman’s panel discussion and plenary lecture, “Caregiving As Moral Experience,” on Penn’s campus this past fall.

At Penn Memory Center, the excitement of a new year brings with it the pride of distributing a new print issue of InSight magazine. This year’s issue is the most comprehensive to date. 

Our cover story is of Julius Hayes, a six-year ABC Study participant whose commitment to research is borne out of a sense of duty towards contributing to the progression of Alzheimer’s treatments. Julius also highlights the importance of including more African-American men in studies, a group severely underrepresented in research. 

Readers will also find updates and information on the Memory Center’s ongoing research, our coverage of Biogen’s shocking aducanamab announcement and patient perspectives on the return of the drug trials, as well as mixture of how science and art blend together for one researcher, and one man’s photographic journey through his father’s life with dementia.

Anyone interested in receiving a free print copy edition of InSight should email terrence.casey@pennmedicine.upenn.edu 

Click here to see previous editions of InSight: pennmemorycenter.org/insight 

By Danny Yarnall

The world of Alzheimer’s research has been flooded with news and speculation surrounding Biogen’s stunning announcement this fall that it would seek FDA approval for its Alzheimer’s drug aducanumab after closing previous studies in March 2019. Some clarity was brought at a Clinical Trials for Alzheimer’s Disease meeting this past December where Biogen released the data behind its reversal on the drug and announced they would reopen aducanumab studies. Still many questions remain as FDA approval process inches closer.

PMC Co-Director Jason Karlawish, MD, wrote twice for STAT News, outlining the significance of this new information and how aducanumab, with its risks, fits into a much larger picture of Alzheimer’s care and management.

“It won’t end Alzheimer’s because it cures the disease. It doesn’t do that. Aducanumab appears to slow, but does not stop, and certainly does not reverse, patients’ cognitive and functional declines…As long as the benefits are judged to outweigh the risks, aducanumab won’t just treat individuals with Alzheimer’s disease. It will treat our Alzheimer’s culture,” Dr. Karlawish wrote.

By Danny Yarnall

The University of Pennsylvania’s partnership with the Centers for Disease Control and Prevention (CDC) promoted Alzheimer’s education and combatted stigma, according to a recent report published by the CDC. The program completed in 2019.

The reports from the Healthy Brain Research Network, released November 3, are summaries of the completed work of the six academic institutions in the network, including the work done by Penn Memory Center’s Penn Program on Precision Medicine for the Brain (P3MB) team. 

By Danny Yarnall

Congressional leaders agreed to a $350 million increase in Alzheimer’s and dementia research funding through the National Institutes of Health (NIH) as a part of a larger NIH budget increase for the 2020 fiscal year.

The agreement broke a three-month deadlock in budget negotiations on Capitol Hill.

The additional funds pushes NIH spending on Alzheimer’s to $2.8 billion, six times the amount originally allocated when the National Alzheimer’s Project Act (NAPA) was passed in 2011. 

On the whole, the NIH budget increased by $2.6 billion from last year and was among many other science and research institutions to enjoy similar bumps in spending. This comes after a proposed budget released by the White House in March showed over $12 billion (14%) in cuts to all research expenditures.

Penn Memory Center Scholar Emily Largent, JD, PhD, RN, was recently named the Emanuel & Robert Hart Assistant Professorship of Medical Ethics and Health Policy.

“It’s an honor to be the new Emanuel & Robert Hart Assistant Professor of Medical Ethics and Health Policy,” Dr. Largent said. “I’ve had the pleasure of meeting Robert Hart and his wife, Ineza, on several occasions and am so grateful for their support.” 

By Sharnita Midgett

On a November Thursday morning, Nancy Fuhrman reported to the Perelman Center for Advanced Medicine for a full shift of work.

But Fuhrman is not employed by Penn Medicine; she is a participant in the Aging Brain Cohort study who scheduled a year’s worth of substudies into a single day. 

Penn Memory Center neurologist Roy Hamilton, MD, MS will be taking a leave from his PMC clinical duties from January until June as he launches a new center at the University of Pennsylvania devoted to stimulating the human brain.

The new Brain Stimulation, Translation, Innovation, and Modulation Center (brainSTIM Center) has been a goal Dr. Hamilton has been working towards in the two decades since he started working in the field of neuromodulation, he said.

“I’m humbled and deeply inspired,” said Dr. Hamilton of the opportunity to start the center. “I’m truly excited to take a leading role in these efforts.”

By Danny Yarnall

Penn Memory Center Co-Director Dr. Jason Karlawish, MD, recently testified on the state of Alzheimer’s and dementia research and care in Washington, D.C. before the Senate Finance subcommittee on health care.

Dr. Karlawish spoke about the progress made in understanding Alzheimer’s disease in the past four decades, from a disease surrounded in confusion that developed into a “gothic horror story” to a disease that can be diagnosed non-invasively and understood by families and physicians alike. He was joined by medical professionals, researchers, and caregivers presenting the barriers and difficulties in Alzheimer’s care today.

“I am sad however that there are still too many persons living with dementia and their families who are telling the same stories told some 40 years ago,” he said in his remarks to subcommittee chair Patrick Toomey (R – PA) and ranking member Debbie Stabenow (D – MI), who led the hearing. The subcommittee on health care focuses on Medicare and Medicaid spending and health programs financed by a specific tax or trust fund.